meglumine antimoniate liposomal

Liposomal meglumine antimoniate is a lipid-encapsulated formulation of the pentavalent antimonial drug meglumine antimoniate, designed to improve the therapeutic index of conventional antimonial therapy for leishmaniasis. By encapsulating the drug in liposomes, it is preferentially taken up by macrophages, the primary host cells for *Leishmania* parasites, thereby increasing drug concentration at the site of infection while reducing systemic exposure and associated toxicities such as cardiotoxicity and nephrotoxicity. This formulation has been investigated for both cutaneous leishmaniasis (via topical application) and visceral leishmaniasis (via systemic administration). Research in animal models and naturally infected dogs has demonstrated that liposomal delivery can achieve significant parasite suppression at doses up to 20-fold lower than those required for the free drug.

Other names

Liposomal meglumine antimoniateLiposomal GlucantimeLiposome-encapsulated meglumine antimoniate